Search company, investor...

Founded Year



Seed - III | Alive

Total Raised


Last Raised

$19.15M | 7 mos ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+10 points in the past 30 days

About Verismo Therapeutics

Verismo Therapeutics develops chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. The company provides several other healthcare facilities such as CAR-T, cell therapy, solid tumor, immuno-oncology, and the KIR-CAR platform. Verismo Therapeutics was founded in 2020 and is based in Philadelphia, Pennsylvania.

Headquarters Location

3675 Market Street Suite 200

Philadelphia, Pennsylvania, 19104,

United States



Verismo Therapeutics's Product Videos

Verismo Therapeutics's Products & Differentiators


    A CAR T cell therapy based on the KIR-CAR platform, exclusively developed by Verismo Therapeutics.


Latest Verismo Therapeutics News

Insights into Cholangiocarcinoma Pipeline 2024: Latest Developments, FDA Approvals, Clinical Trials, and Therapeutic Innovations Unveiled by DelveInsight | Merck, Eisai, Janssen Research, 3D Medicines

Feb 15, 2024

Cholangiocarcinoma Pipeline (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cholangiocarcinoma pipeline constitutes 55+ key companies continuously working towards developing 60+ Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. “ Cholangiocarcinoma Pipeline Insight, 2024 “ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cholangiocarcinoma Market. Some of the key takeaways from the Cholangiocarcinoma Pipeline Report: Companies across the globe are diligently working toward developing novel Cholangiocarcinoma treatment therapies with a considerable amount of success over the years. Cholangiocarcinoma companies working in the treatment market are Well Marker Bio, Sirnaomics, Kinnate Biopharma, Medivir, Eisai Co., Ltd., TransThera Biosciences, Hutchison Medipharma Limited, RedHill Biopharma Limited, Compass Therapeutics, Merck Sharp & Dohme, Eisai, Merck & Co, Zymeworks and BeiGene, Decalth Systems, Basilea Pharmaceutica, AstraZeneca, Taiho Oncology, and others, are developing therapies for the Cholangiocarcinoma treatment Emerging Cholangiocarcinoma therapies in the different phases of clinical trials are- WM-S1, STP-705, KIN-3248, MIV-818, E7090, TT-00420, HMPL-453, ABC294640, CTX-009, KEYTRUDA (pembrolizumab), Tasurgratinib (E7090), LENVIMA (lenvatinib), Zanidatamab, Melphalan, Derazantinib, Imfinzi (durvalumab), TAS-120 (futibatinib), and others are expected to have a significant impact on the Cholangiocarcinoma market in the coming years. In May 2023, Richard Kim discussed the investigation of RLY-4008 as a treatment for individuals diagnosed with cholangiocarcinoma possessing an FGFR2 fusion or rearrangement. RLY-4008, an exceptionally selective and irreversible FGFR2 inhibitor, is presently undergoing assessment in the phase 1/2 REFOCUS trial (NCT04526106). Initial data presented at the 2022 ESMO Congress revealed that among patients with FGFR inhibitor–naïve cholangiocarcinoma and an FGFR2 fusion or rearrangement (n = 17), there was an observed overall response rate of 88.2%. In April 2023, Nuvectis Pharma shared key findings from the poster presentation of NXP800 during the American Association for Cancer Research (“AACR”) Annual Meeting 2023 held in Orlando, FL. The strong preclinical efficacy displayed by NXP800 in cholangiocarcinoma patient-derived xenograft (PDX) models is seen as a promising sign for potential clinical advantages. Cholangiocarcinoma is notably challenging to treat, often resulting in unfavorable outcomes, and these recent findings offer hope for future treatment prospects for patients. In April 2023, Verismo Therapeutics has been granted fast-track designation by the US Food and Drug Administration (FDA) for its investigational new drug, SynKIR-110. SynKIR-110 is an experimental medication aimed at addressing severe diseases and life-threatening conditions, specifically targeting mesothelin-expressing mesothelioma, ovarian cancer, and cholangiocarcinoma. In January 2023, Taiho Oncology, Inc. has announced the publication of findings from the pivotal Phase 2 FOENIX*-CCA2 clinical trial of futibatinib in The New England Journal of Medicine (NEJM) on January 19, 2023. The trial demonstrated substantial clinical benefits of futibatinib in patients previously treated for FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma (iCCA). The results revealed an objective response rate of 42% upon independent review, with a median response duration of 9.7 months. Futibatinib exhibited enduring responses and survival rates that exceeded historical chemotherapy data for previously treated iCCA patients. In October 2022, Invitae has formed a collaboration with AstraZeneca, leveraging Invitae’s Ciitizen natural history data for a comprehensive examination involving retrospective and prospective studies of individuals diagnosed with cholangiocarcinoma, a rare cancer affecting the bile duct. This partnership facilitates the exchange of meticulously curated, patient-consented data sourced from the Cholangiocarcinoma Foundation (CCF), a prominent patient advocacy group dedicated to discovering a cure and enhancing the lives of individuals impacted by cholangiocarcinoma. In November 2022, The FDA has awarded orphan drug designation for ZB131 in the treatment of cholangiocarcinoma, as confirmed by the drug’s manufacturer. ZB131, developed by ZielBio, is a monoclonal antibody that demonstrates high affinity and specificity for cancer-specific plectin. Cholangiocarcinoma Overview A type of cancer known as cholangiocarcinoma develops in the cells lining the bile duct, which serves as the liver’s drainage channel for bile. Bile duct cancer, another name for this rare type of cancer, usually affects adults over 50, however it can strike anyone at any age. WM-S1: Well Marker Bio Tasurgratinib (E7090): Eisai Zanidatamab: Zymeworks and BeiGene Further Cholangiocarcinoma product details are provided in the report. Download the Cholangiocarcinoma pipeline report to learn more about the  emerging Cholangiocarcinoma therapies Some of the key companies in the Cholangiocarcinoma Therapeutics Market include: Key companies developing therapies for Cholangiocarcinoma are –  Merck KGaA, Eisai Inc., Janssen Research & Development, LLC, 3D Medicines, Basilea Pharmaceutica, Hutchison Medipharma Limited, Jiangsu HengRui Medicine, TransThera Sciences, RedHill Biopharma, Eli Lilly and Company, Elevation oncology, Senhwa Biosciences, InnoCare Pharma, Genoscience Pharma, Intensity therapeutics, Elucida Oncology, GlaxoSmithKline, Verismo Therapeutics, Sirnaomics, Toray Industries, Inc, Kinnate Biopharma, Boehringer Ingelheim, Wellmarker Bio, Arbele Limited, NGM Biopharmaceuticals, Inc., Elicio Therapeutics, Xencor, Inc., Celon Pharma SA, and others. The Cholangiocarcinoma pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Cholangiocarcinoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cholangiocarcinoma Treatment. Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cholangiocarcinoma market. The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Cholangiocarcinoma Pipeline Market Drivers Increasing Incidence of Cholangiocarcinoma, increasing R&D Activities, increasing Awareness are some of the important factors that are fueling the Cholangiocarcinoma Market. Cholangiocarcinoma Pipeline Market Barriers However, high cost of drugs, high Incidence of adverse events and other factors are creating obstacles in the Cholangiocarcinoma Market growth. Coverage: Global Key Cholangiocarcinoma Companies: Well Marker Bio, Sirnaomics, Kinnate Biopharma, Medivir, Eisai Co., Ltd., TransThera Biosciences, Hutchison Medipharma Limited, RedHill Biopharma Limited, Compass Therapeutics, Merck Sharp & Dohme, Eisai, Merck & Co, Zymeworks and BeiGene, Decalth Systems, Basilea Pharmaceutica, AstraZeneca, Taiho Oncology, and others Key Cholangiocarcinoma Therapies: WM-S1, STP-705, KIN-3248, MIV-818, E7090, TT-00420, HMPL-453, ABC294640, CTX-009, KEYTRUDA (pembrolizumab), Tasurgratinib (E7090), LENVIMA (lenvatinib), Zanidatamab, Melphalan, Derazantinib, Imfinzi (durvalumab), TAS-120 (futibatinib), and others Cholangiocarcinoma Therapeutic Assessment: Cholangiocarcinoma current marketed and Cholangiocarcinoma emerging therapies Cholangiocarcinoma Market Dynamics: Cholangiocarcinoma market drivers and Cholangiocarcinoma market barriers

Verismo Therapeutics Frequently Asked Questions (FAQ)

  • When was Verismo Therapeutics founded?

    Verismo Therapeutics was founded in 2020.

  • Where is Verismo Therapeutics's headquarters?

    Verismo Therapeutics's headquarters is located at 3675 Market Street, Philadelphia.

  • What is Verismo Therapeutics's latest funding round?

    Verismo Therapeutics's latest funding round is Seed - III.

  • How much did Verismo Therapeutics raise?

    Verismo Therapeutics raised a total of $52.15M.

  • Who are the investors of Verismo Therapeutics?

    Investors of Verismo Therapeutics include HLB, Dongkoo Bio&Pharma, Ignite Innovation, BRV Capital Management and University of Pennsylvania.

  • Who are Verismo Therapeutics's competitors?

    Competitors of Verismo Therapeutics include TCR2 Therapeutics and 1 more.

  • What products does Verismo Therapeutics offer?

    Verismo Therapeutics's products include SynKIR.


Compare Verismo Therapeutics to Competitors

TCR2 Therapeutics

TCR2 Therapeutics (NASDAQ: TCRR) is a discovery-stage pharmaceutical company that focuses on engineering T cells for cancer therapy. The company's expertise in T cell engagement and an understanding of T cell receptor biology helps to kill cancer cells by harnessing the entire TCR signaling complex. The company was founded in 2015 and is based in Cambridge, Massachusetts. In June 2023, TCR2 Therapeutics was acquired by Adaptimmune at a valuation of $110M.


Lyell (NASDAQ: LYEL) operates as a cellular therapy company. The company offers T lymphocyte cell (T-cell) reprogramming technologies designed to address major barriers to successful adoptive cell therapy (ACT) for solid tumors. It was founded in 2018 and is based in South San Francisco, California.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.